adalimumab-atto (Amjevita) vs adalimumab-ryvk (Simlandi)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Rheumatoid Arthritis

Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline

adalimumab-atto (Amjevita)

Marketed by Amgen

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT01970475 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled trial of 526 participants, with adalimumab as the comparator. The clinical primary endpoint, ACR20 response at week 24, met the prespecified equivalence criterion: the 90% confidence interval for the response risk ratio (0.954–1.133) was within the equivalence margins (0.738–1.355).

Reported efficacy

Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): ABP 501 74.6 percentage of participants | Adalimumab 72.4 percentage of participants (met)

Result source: NCT01970475

adalimumab-ryvk (Simlandi)

Marketed by Alvotech and partners

Approved in Rheumatoid Arthritismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-atto (Amjevita)adalimumab-ryvk (Simlandi)
ACR2074.6% vs 72.4%vs Adalimumabwk 24 · n 260NCT01970475
2 other results
  • 63.5% vs 62.5% wk 8 · n 264 · Phase 3 · secondary NCT01970475
  • 35.4% vs 24.5% wk 2 · n 264 · Phase 3 · secondary NCT01970475
—Not reported
ACR5049.2% vs 52%vs Adalimumabwk 24 · n 244NCT01970475—Not reported
ACR7026% vs 22.9%vs Adalimumabwk 24 · n 246NCT01970475—Not reported
DAS28-CRP remission—Not reported—Not reported
HAQ-DI, change—Not reported—Not reported
Modified Sharp score, change—Not reported—Not reported

ACR20

adalimumab-atto (Amjevita)
74.6% vs 72.4%vs Adalimumabwk 24 · n 260NCT01970475
2 other results
  • 63.5% vs 62.5% wk 8 · n 264 · Phase 3 · secondary NCT01970475
  • 35.4% vs 24.5% wk 2 · n 264 · Phase 3 · secondary NCT01970475
adalimumab-ryvk (Simlandi)
—Not reported

ACR50

adalimumab-atto (Amjevita)
49.2% vs 52%vs Adalimumabwk 24 · n 244NCT01970475
adalimumab-ryvk (Simlandi)
—Not reported

ACR70

adalimumab-atto (Amjevita)
26% vs 22.9%vs Adalimumabwk 24 · n 246NCT01970475
adalimumab-ryvk (Simlandi)
—Not reported

DAS28-CRP remission

adalimumab-atto (Amjevita)
—Not reported
adalimumab-ryvk (Simlandi)
—Not reported

HAQ-DI, change

adalimumab-atto (Amjevita)
—Not reported
adalimumab-ryvk (Simlandi)
—Not reported

Modified Sharp score, change

adalimumab-atto (Amjevita)
—Not reported
adalimumab-ryvk (Simlandi)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-ryvk (Simlandi): no structured comparison results are available for Rheumatoid Arthritis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab-atto (Amjevita): 4 of 4 rows · adalimumab-ryvk (Simlandi): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab-atto (Amjevita)
Dropout rate
8%a
NCT01970475 · Phase 3
Discontinued due to AEs
2.7%a
NCT01970475 · Phase 3
Serious AEs
3.8%a
NCT01970475 · Phase 3
Most frequent reported AEs
a
nasopharyngitis 6.4%
NCT01970475 · Phase 3

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab-atto (Amjevita)

ACR20 74.6% (n=260) vs 72.4% (n=261) Adalimumab @ 24wk
responder rate · % of participants
NCT01970475 · Phase 3
show 2 more results
35.4% (n=264) vs 24.5% (n=262) Adalimumab @ 2wk
NCT01970475 · Phase 3
63.5% (n=264) vs 62.5% (n=262) Adalimumab @ 8wk
NCT01970475 · Phase 3
DAS28-CRP -1.01 vs -0.96 Adalimumab score @ 2wk
absolute change · score
NCT01970475 · Phase 3
show 5 more results
-1.45 vs -1.42 Adalimumab score @ 4wk
NCT01970475 · Phase 3
-1.79 vs -1.7 Adalimumab score @ 8wk
NCT01970475 · Phase 3
-2.04 vs -1.93 Adalimumab score @ 12wk
NCT01970475 · Phase 3
-2.3 vs -2.17 Adalimumab score @ 18wk
NCT01970475 · Phase 3
-2.32 vs -2.32 Adalimumab score @ 24wk
NCT01970475 · Phase 3
ACR50 49.2% (n=244) vs 52% (n=252) Adalimumab @ 24wk
responder rate · % of participants
NCT01970475 · Phase 3
ACR70 26% (n=246) vs 22.9% (n=253) Adalimumab @ 24wk
responder rate · % of participants
NCT01970475 · Phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-atto (Amjevita)'s landscape · adalimumab-ryvk (Simlandi)'s landscape